Triple threat: new combo aims to stop pancreatic cancer spread
NCT ID NCT02648282
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of a pancreatic cancer vaccine (GVAX), an immunotherapy drug (pembrolizumab), and focused radiation (SBRT) in 58 patients with locally advanced pancreatic cancer. The goal was to see if this approach could delay the spread of the cancer to other parts of the body. Participants had already received standard chemotherapy before joining the study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pancreatic cancer vaccine (GVAX) plus pembrolizumab (immunotherapy) and stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this combination could delay or prevent the spread of pancreatic cancer, offering a new treatment option for patients with locally advanced disease.
What could go wrong
This is a small, early-phase trial (58 participants) with no control group, so results may not be definitive. The combination therapy carries risks of serious side effects, including immune-related toxicities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sidney Kimmel Comprehensive Cancer at Johns Hopkins
Baltimore, Maryland, 21231, United States